A national conversation with an unparalleled look into the leading minds that are shaping today's public health decisions, economic policies, regulatory and governance, and the emergence of a new normal.
Site
RSS
Apple
Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
Discover shows related to Findmyvaccine Podcast, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
Antibodies, Vaccines & Baby Season: An RSV Prevention Masterclass with Dr. Zain Chagla PART 2
Season 1 · Episode 32
Wednesday, August 19, 2026 • Duration 23:25
Episode Description
RSV prevention now comes with options. Great news—until you have to decide who gets what, when, and how to make sure it actually happens. 🦠💉
In Part 2 of our conversation, infectious disease specialist Dr. Zain Chagla returns to the FindMyVaccine Podcast to take RSV prevention from the guideline page to the front lines.
First up: timing really is everything. A baby born during RSV season may be best protected before leaving hospital. A baby born in July? Not so fast. Dr. Chagla explains why the goal isn’t simply to immunize at the earliest opportunity—it’s to line up the protection window with the infant’s period of greatest RSV exposure. Think less “ASAP” and more “right place, right season.”
Then comes the big practical question: maternal vaccination or infant monoclonal antibody?
We unpack gestational timing, the important two-week window before delivery, infant risk factors, family preference, local program availability—and why this conversation belongs in the birth plan, not as a surprise item at discharge.
With multiple monoclonal antibody options now in the toolkit, we also ask: how do you actually choose one?
Dr. Chagla walks through dosing, age and season indications, access, inventory and workflow considerations.
And because guidelines always sound easier until an actual patient walks in, we put Zain through a special rapid-fire RSV rounds. ⚡
Four babies. Four different scenarios. No multiple-choice answers.
A healthy baby born in July.
A newborn delivered nine days after maternal RSV vaccination.
A premature infant.
A 14-month-old with chronic lung disease heading into season two.
Dr. Chagla offers a practical way to explain risk without frightening parents or overselling protection.
Finally, we finish with a Monday-morning checklist for clinicians. Because ultimately, the best RSV strategy isn’t necessarily the fanciest one.
Learning Objectives
By the end of this episode, listeners will be able to:
Apply RSV seasonality to prevention timing, distinguishing the approach for infants born during versus outside peak RSV activity.
Compare maternal RSV vaccination and infant monoclonal antibody strategies, considering gestational timing, infant risk, family preference and local program availability.
Recognize situations where monoclonal antibody protection may still be appropriate, including insufficient time between maternal vaccination and delivery or increased infant risk.
Evaluate practical factors involved in monoclonal antibody selection, including authorized indications, dosing, age, workflow, accessibility and second-season considerations.
Apply RSV prevention recommendations to common real-world cases, including healthy infants, premature newborns and medically high-risk children.
Counsel parents about RSV risk in a balanced and understandable way, setting realistic expectations about what preventive interventions can—and cannot—do.
Identify practical system changes that can improve RSV prevention,
Dr.Zain Chagla, MD MSc MD, FRCPC is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla is also a teacher at McMaster University where he won a clinician teaching award in internal medicine and a young investigator grant for his work in supporting undergraduate medical education at the University of Namibia.
Dr. Chagla also has a Master of Science in infectious diseases and a diploma in tropical medicine and hygiene from the London School of Hygiene & Tropical Medicine.
As an infectious disease specialist, Dr.Zain Chagla has given media interviews on the COVID-19 pandemic and published several op-eds on testing, disease elimination, and public health interventions. He has contributed to local, provincial, and federal policy planning, and to several clinical trials on COVID-19 therapies. He has published works on COVID-19 research, epidemiology, testing, and infection control. He is involved with a prospective cohort study looking at respiratory physiology and radiologic features of patients post covid with persistent symptoms over time, including those with long covid and those who were critically ill.
Antibodies, Vaccines & Baby Season: An RSV Prevention Masterclass with Dr. Zain Chagla
Season 1 · Episode 31
Monday, August 17, 2026 • Duration 26:24
Episode Description
RSV prevention has entered its “more options, more questions” era. 👶🦠
In Part 1, infectious disease specialist Dr. Zain Chagla returns to the FindMyVaccine Podcast to help sort through what Canadian clinicians actually need to know about protecting infants from RSV.
First up: who is really at risk? Spoiler—the answer is not just premature or medically fragile babies. Dr. Chagla explains why otherwise healthy, full-term infants can still end up hospitalized with RSV, why those first few months of life matter so much, and how to communicate that risk to families without turning counselling into a horror movie.
We then tackle the updated NACI guidance and the increasingly important choice between maternal vaccination and long-acting monoclonal antibodies. Who should receive what? When does maternal vaccination leave an infant needing additional protection? And which higher-risk babies deserve a particularly proactive plan?
Then comes the immunology—minus the painful lecture.
Dr. Chagla explains why monoclonal antibodies are not vaccines, how passive immunization essentially gives infants ready-made RSV-fighting antibodies, and why newer long-acting options have changed the game from repeated injections to protection that can potentially cover much of an RSV season.
And because percentages alone rarely tell the whole story, we dig into the evidence: pivotal trials, hospitalization outcomes, absolute risk reduction, high-risk infant data, and why comparing one RSV monoclonal antibody trial directly with another can get scientifically… messy.
Bottom line: RSV prevention is no longer simply about knowing that options exist. It is about knowing which option, for which infant, at which time.
Class is officially in session. 🎙️
Learning Objectives
By the end of this episode, listeners will be able to:
🎙️🎙️🎙️ MINI EPISODE 1: A Conversation with Dr.Sonia Anand MD, PhD, FRCPC
💡 💡 💡Ensuring immunization of structurally disadvantaged populations: Black People and other people of colour
Podcast Learning objectives
• Describe how race-disaggregated data can allow for more targeted, community-specific interventions.
• Apply novel community-specific work to engage communities to support immunization.
• Illustrate how anti-Black racism presents a pervasive barrier to engaging with preventive health care initiatives.
For this mini podcast, we delve into how historical and systemic racism creates hurdles not only in understanding vaccine coverage discrepancies in Canada, but also in crafting effective, nuanced responses. We spotlight the distinctive obstacles Black and Asian communities in Canada have faced in accessing vaccines, both amidst the pandemic and prior to it. In the absence of detailed race-specific data for monitoring diseases preventable by vaccines and tracking vaccination rates, it is difficult to adequately cater to marginalized communities who face systemic barriers to healthcare access, including vaccinations. Dr.Anand unpacks this complex issue.
A New Deal for Canadian Healthcare with Prime Minister Justin Trudeau
🍁🎬 The premiers and the prime minister reached a new 10 year healthcare funding deal totaling $196 billion, with $46 billion in new funding with a tailored approach to the unique healthcare needs of each province and territory via bilateral deals. Provinces and territories in return must commit to health-care reform and improve transparency around data collection.
🍁▶️ We sit down with Canadian Prime Minister, Justin Trudeau, to chat about his vision for healthcare, opportunities and challenges, and what building accountability and innovation into these new bilateral healthcare agreements with each province and territory will, and can look like.
🍁🎙️ 🗨️ Whether you practice in BC or Newfoundland, 𝙬𝙝𝙚𝙩𝙝𝙚𝙧 𝙮𝙤𝙪'𝙧𝙚 𝙖 pharmacist, physician, nurse, nurse practitioner, or allied health professional, tune in to hear the PM’s personal message for our listeners and how the next generation of leaders in healthcare can play a meaningful role in shaping future of our healthcare system.
BC Premier David Eby on Healthcare in BC
Season 1 · Episode 20
Friday, November 18, 2022 • Duration 41:02
🎬NOTE: Episode recorded in early Fall (September) as leadership candidate prior to David officially becoming Premier. ******
☎️ Today, David Eby was sworn in as British Columbia’s 37th premier.
🗨️ We sit down with Premier Eby to discuss his plans for the Province's #𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝘀𝘆𝘀𝘁𝗲𝗺, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 everything from 𝗲𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 #patient 𝗮𝗰𝗰𝗲𝘀𝘀 by expanding 𝘁𝗵𝗲 𝘀𝘂𝗶𝘁𝗲 𝗼𝗳 𝘀𝗲𝗿𝘃𝗶𝗰𝗲𝘀 #𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝘀𝘁𝘀 𝗮𝗻𝗱 𝗼𝘁𝗵𝗲𝗿 #𝗛𝗖𝗣𝘀 𝗰𝗼𝘂𝗹𝗱 𝗽𝗿𝗼𝘃𝗶𝗱𝗲, reforming primary care, and if outdated legislation around patient rights is meeting the needs of today's patients.
Climate Change, Communication and Mobilizing Public Health with Canada's Top Doctor: Dr.Theresa Tam
Season 1 · Episode 19
Tuesday, October 18, 2022 • Duration 38:28
▶️ 🗨️ We are excited to sit down with Canada's Chief Public Health Officer, Dr.Theresa Tam, to discuss her personal thoughts about how this pandemic has reshaped how we think about public health's role and new opportunities to synergize with frontline healthcare providers.
🎬🎙️ Often climate change is not a top of mind issue when it comes to healthcare planning and resource allocation. In anticipation of Dr.Tam's upcoming Annual report, we deep dive into how public health is building in plans to address climate change, extreme weather event, and the changing endemicity of transmissible diseases as a result.
💡 You also don't want to miss Dr.Tam's secret talent.
🎬NOTE: Links added below to Dr.Theresa Tam's Annual Report: Mobilizing Public Health Action on Climate Change in Canada as episode was recorded prior to release******
04:21 Dr.Tam's journey from practitioner to public health leader
07:48 Dealing with being a very public face and the pressures that come with it
14:55 Planning for the future of public health in Canada and the next "x" factor
21:18 Addressing gaps and needs in healthcare communication
Covid-19 Bivalent Boosters — All You Need to Know with Dr.Zain Chagla
Season 1 · Episode 18
Monday, October 3, 2022 • Duration 35:11
Your COVID vaccine is getting a makeover (well kind of).
Freshly formulated updated Omicron-specific COVID-19 vaccines are now available.
These new bivalent booster shots rolling out across Canada are specifically tailored to match currently circulating COVID omicron variants and are thought to provide enhanced protection against newer versions of SARS-CoV-2 than our earlier shots. Uptake of booster vaccines has not been anywhere near as high as the initial vaccines.
▶️🎧 🎙️ 𝐖𝐞 𝐬𝐢𝐭 𝐝𝐨𝐰𝐧 𝐰𝐢𝐭𝐡 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐞𝐱𝐩𝐞𝐫t, 𝐃𝐫.𝐙𝐚𝐢𝐧 𝐂𝐡𝐚𝐠𝐥𝐚 who breaks down all you need to know about (in less than 36 minutes):
✔️✔️How do you approach and recommend the updated bivalent COVID-19 booster to eligible patients
✔️✔️How should you be framing the efficacy conversation in relation to this bivalent booster-antibody data vs clinical effectiveness
✔️✔️Strategies to increase booster uptake in clinical practice
✔️✔️Key practicalities of the vaccine and how this would fit into your daily practice?
✔️✔️Are breakthrough infections less likely with this updated bivalent booster?
✔️✔️Will this booster still work if the virus mutates again and there’s a new variant?
✔️✔️ What does the healthcare provider need to know from this discussion to communicate with a patient the next day?
Dr. Zain Chagla
Dr.Zain Chagla, MD MSc MD, FRCPC is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla is also a teacher at McMaster University where he won a clinician teaching award in internal medicine and a young investigator grant for his work in supporting undergraduate medical education at the University of Namibia.
Dr. Chagla also has a Master of Science in infectious diseases and a diploma in tropical medicine and hygiene from the London School of Hygiene & Tropical Medicine.
Long Story Short? Long COVID and the Role of Vaccination with Dr.Angela Cheung and Dr.Zain Chagla PART 2
Dr. Angela Cheung is the KY and Betty Ho Chair of Integrative Medicine at the University of Toronto and is a professor of medicine and internal medicine specialist, as well as a senior scientist at the University Health Network in Toronto. Dr.Cheung holds a Tier 1 Canada Research Chair and She obtained her M.D. degree from Johns Hopkins University School of Medicine, and her Ph.D. degree from Harvard University.
Dr. Zain Chagla
Long Story Short? Long COVID and the Role of Vaccination with Dr.Angela Cheung and Dr.Zain Chagla
Dr. Angela Cheung is the KY and Betty Ho Chair of Integrative Medicine at the University of Toronto and is a professor of medicine and internal medicine specialist, as well as a senior scientist at the University Health Network in Toronto. Dr.Cheung holds a Tier 1 Canada Research Chair and She obtained her M.D. degree from Johns Hopkins University School of Medicine, and her Ph.D. degree from Harvard University.
Dr. Zain Chagla
FRENCH: Avons-nous besoin de redefinir qui est à haut risque pour les doses de rappel COVID? Avec Dr.Brian Conway
Season 1 · Episode 15
Monday, July 25, 2022 • Duration 56:28
▶️▶️ Les patients à haut risque voient aujourd'hui une combinaison de variantes COVID plus transmissibles et de vaccins dont l'efficacité peut diminuer.
Mais lorsque nous pensons aux patients à haut risque et aux patients cliniquement vulnérables, nous pensons souvent à la population de patients IC. Que diriez-vous si vous êtes obèse ou souffrez de diabète, d'insuffisance cardiaque, d'hypercholestérolémie, d'hypertension ? Qu'en est-il de ceux qui ont des handicaps cognitifs ou physiques spécifiques ? Qu'est-ce qu'un risque élevé au-delà de la population de patients immunodéprimés ?
Nous sommes rejoints par deux experts en maladies infectieuses qui dispensent une masterclass en temps réel sur l'évaluation du risque de COVID chez vos patients et connectent les données émergentes autour des 1er et 2e rappels du vaccin COVID-19.
📰 📺 Les fameuses questions "Demandez à l'expert" de cet épisode explorent des facteurs de risque spécifiques au-delà de l'âge et comment traduire et encadrer efficacement la conversation de rappel en première ligne avec votre patient. Comment dépister et communiquer en première ligne ? Et comment regardons-nous les conseils du NACI sur les rappels par rapport aux recommandations du JCVI pour l'automne ?
OBJECTIFS D'APPRENTISSAGE DE L'ÉPISODE :
o Explorer la compréhension et la définition actuelles des populations de patients à haut risque et comment stratifier le risque dans le contexte de la progression vers une maladie COVID-19 sévère en fonction des comorbidités
o Démontrer comment les prestataires de soins de santé de première ligne peuvent dépister efficacement les patients présentant des comorbidités pour des doses de rappel COVID-19
o Décrire comment encadrer efficacement la communication des vaccins de rappel COVID-19 dans le contexte des questions cliniques réelles des patients
Describe the clinical burden of RSV in infants and explain why severe disease can occur even in previously healthy, full-term babies.
Interpret updated Canadian RSV prevention guidance, including the respective roles of maternal vaccination and infant monoclonal antibodies.
Identify infants who may warrant a more proactive monoclonal antibody strategy, including those with prematurity, cardiopulmonary disease, immunodeficiency, other medical risk factors, or barriers to timely healthcare access.
Explain the difference between vaccination and passive immunization, including how long-acting monoclonal antibodies provide immediate protection against RSV.
Translate RSV clinical trial results into practical clinical meaning, including relative efficacy, absolute reductions in hospitalization, and important limitations when comparing evidence across trials.
Apply seasonality and local RSV surveillance when considering the timing of infant prevention strategies.
Dr.Zain Chagla, MD MSc MD, FRCPC is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla is also a teacher at McMaster University where he won a clinician teaching award in internal medicine and a young investigator grant for his work in supporting undergraduate medical education at the University of Namibia.
Dr. Chagla also has a Master of Science in infectious diseases and a diploma in tropical medicine and hygiene from the London School of Hygiene & Tropical Medicine.
As an infectious disease specialist, Dr.Zain Chagla has given media interviews on the COVID-19 pandemic and published several op-eds on testing, disease elimination, and public health interventions. He has contributed to local, provincial, and federal policy planning, and to several clinical trials on COVID-19 therapies. He has published works on COVID-19 research, epidemiology, testing, and infection control. He is involved with a prospective cohort study looking at respiratory physiology and radiologic features of patients post covid with persistent symptoms over time, including those with long covid and those who were critically ill.
About Dr.Sonia Anand MD, PhD, FRCPC
Professor of Medicine and Epidemiology, McMaster
Senior Scientist Population Health Research Institute
Tier 1 Canada Research Chair in Ethnic Diversity and Cardiovascular Disease
Heart and Stroke Chair in Population Health
Associate Chair of Equity and Diversity, Department of Medicine
Director of Chanchlani Research Centre
Dr. Sonia Anand is a professor in the Department of Medicine, and the Director of the Population Genomics Program, at McMaster. She is also a senior scientist at the Population Health Research Institute at Hamilton Health Sciences. Dr. Anand holds a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease, and the Heart and Stroke Foundation of Ontario/Michael G. DeGroote Chair in Population Health Research. In 2010, Dr. Anand was named among the top 100 women by the Women’s Executive Network for her accomplishments in research and medicine. Her current research focuses on environmental and genetic determinants of vascular disease in populations of varying ancestral origin, women and cardiovascular disease.
🎙️🎙️🎙️ MINI EPISODE 2: A Conversation with Dr.Wayne Ghesquiere MD, FRCPC
💡 💡 💡Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: Interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination
Podcast Learning objectives
• Discuss the interim efficacy of the adjuvanted recombinant zoster vaccine approximately 10 years post-vaccination.
• Explain the immunogenicity of the adjuvanted recombinant zoster vaccine and how it contributes to its long-term protection against herpes zoster.
• Evaluate the safety profile of the adjuvanted recombinant zoster vaccine based on data collected over approximately 10 years.
• Analyze the significance of these interim results in the context of long-term vaccine strategies against herpes zoster.
• Incorporate the provided insights into clinical practice and future research regarding herpes zoster vaccination strategies.
• Communicate effectively to patients about the long-term benefits and safety of the adjuvanted recombinant zoster vaccine
About Dr.Wayne Ghesquire MD, FRCPC
Dr Wayne Ghesquiere is a Clinical Infectious Diseases, Tropical Diseases and Internal Medicine consultant in Victoria BC as well as the former section chief for infectious diseases with the Vancouver Island Health Authority, VIHA.
Wayne is a Clinical Assistant Professor of Medicine with University of British Columbia. Teaches internal medicine residents and infectious diseases fellows. He is an attending physician at the Royal Jubilee and the Victoria General Hospitals in Victoria, BC. He has an inpatient and a private outpatient practice in infectious diseases.
Wayne is the chair and organizer of the annual Infectious Diseases Update in Victoria now in it’s 26th year. He is also the medical director of the Nova Travel Medicine and Immunization Clinic in Victoria.
Current areas of interests include clinical research in Hepatitis B and C antiviral therapies, new vaccines, and teaching. He is a principal investigator of many clinical trials. He has publications in peer-reviewed medical journals including the NEJM, Lancet, Clinical Infectious Diseases, CMAJ, Open Medicine and others.
🎙️🎙️🎙️ MINI EPISODE 3: A Conversation with Dr. Juthaporn Cowan, MD, FRCPC
💡 💡 💡Management of COVID-19 in immunocompromised patients: Are you up to date?
This podcast episode is centered around COVID-19 protection strategies for immunocompromised patients. Additionally, listeners will gain up to date insight into the range of tools available for these patients' protection and treatment, including antivirals and both active and passive vaccination methods. We'll also tackle ongoing concerns regarding the management of COVID-19 amidst the persistent emergence of new variants, emphasizing the necessity of regular revisits and modifications to these management strategies.
Podcast Learning Objectives
Describe the medical challenges faced by immunocompromised patients and discuss the unmet need for additional protection against SARS – CoV-2.
Address the most recent data for prevention and treatment of COVID-19 in immunocompromised patients including the use of monoclonal antibodies.
Share best practices for the optimum clinical management of COVID-19 in immunocompromised patients in the current Canadian context.
About Dr. Juthaporn Cowan, MD, FRCPC
Assistant Professor, Associate Scientist, The Ottawa Hospital Research Institute
Dr.Juthaporn Cowan is an Associate Scientist at The Ottawa Hospital Research Institute, Assistant Professor at The University of Ottawa, cross-appointed Assistant Professor at the Department of Biochemistry, Microbiology and Immunology and a Physician for the Division of Infectious Diseases at The Ottawa Hospital.
Dr. Cowan began her training at Mahidol University in Thailand for her MD. She also obtained a PhD in Microbiology and Immunology at Kyoto University in Kyoto, Japan. She completed a Postdoctoral Fellowship at The Ottawa Hospital Research Institute. Her research at the time focused on Tuberculosis and immunopathogenesis. She then started her Internal Medicine training at the University of Ottawa. During her postgraduate training her interest shifted from tuberculosis to infection in immunodeficiency patients. Subsequently, she completed a Clinical Fellowship in Infectious Diseases with the University of Ottawa. Drs.D.William Cameron and Cowan run an immunodeficiency/immunoglobulin treatment clinic in Ottawa
The Right Honourable Justin Trudeau, Prime Minister of Canada
Justin Trudeau is Canada’s 23rd Prime Minister.
Justin’s vision of Canada is a country where everyone has a real and fair chance to succeed. His experiences as a teacher, father, leader, and advocate for youth have shaped his dedication to Canadians – and his commitment to make Canada a place where everyone has the opportunities they need to thrive.
The oldest of three boys, Justin grew up with the profound influence of his father, Pierre Elliott Trudeau, and his mother, Margaret Trudeau. He was raised speaking both French and English and has family roots in both Eastern and Western Canada. This background helped spark his passion for public service and shaped his conviction that diversity is Canada’s strength.
Justin studied literature at McGill University, graduating with a Bachelor of Arts (B.A.) in 1994. He went on to complete the University of British Columbia’s education program, and spent several years teaching French, math, and other subjects in Vancouver. Teaching allowed him to make a positive impact in the lives of young people. He remains committed to hearing the voices of young Canadians, from the classroom to Parliament Hill.
Before entering politics, Justin served as the Chair of Katimavik, on the board for the Canadian Avalanche Foundation, and as an advocate for young people and the environment. As a speaker at events and conferences around the country, he encouraged young people to engage with the issues important to them and participate as active citizens. These experiences made it increasingly clear to him that the issues young Canadians care about – education, the environment, and their generation's economic prospects – needed a stronger voice.
Justin entered politics to make change that would better serve all Canadians. In 2007, he built a community-based, grassroots campaign to win the Liberal Party nomination in the Montréal riding of Papineau. He was elected in 2008, and re-elected in 2011, 2015, and 2019.
Justin was elected Leader of the Liberal Party in April 2013. His leadership campaign focused on building a new, truly national movement of progressive Canadians, bringing hundreds of thousands of Canadians into politics, most for the first time. He worked closely with his team to build a plan to create jobs, grow the economy, protect the environment, and strengthen the middle class. With Justin’s leadership, the Liberal plan emphasized fair economic opportunity for everyone, respect for and promotion of freedom and diversity, and a more democratic government that truly represents Canadians.
On October 19, 2015, Justin led his party to victory, winning a majority government with seats in every province and territory across the country. He was sworn in on November 4, 2015.
On October 21, 2019, Justin led the Liberal Party to re-election, earning a second mandate from Canadians.
As Prime Minister, Justin leads a government that works hard every day to continue moving Canada forward. His team is focused on creating good middle class jobs, making life more affordable, keeping Canada’s communities safe, fighting climate change, and moving forward on reconciliation with Indigenous peoples. A proud feminist, Justin appointed Canada’s first gender balanced Cabinet.
VODCAST OF THIS EPISODE AVAILABLE HERE: https://www.myvaccinepodcast.com/vodcast#Trudeau
🎙️𝗪𝗵𝗮𝘁 𝘄𝗶𝗹𝗹 𝗶𝘁 𝘁𝗮𝗸𝗲 𝘁𝗼 𝗺𝗮𝗸𝗲 𝘁𝗵𝗲 𝘀𝗵𝗶𝗳𝘁 broadly across our healthcare 𝗳𝗿𝗼𝗺 #𝘃𝗼𝗹𝘂𝗺𝗲 𝘁𝗼 #𝘃𝗮𝗹𝘂𝗲 𝗯𝗮𝘀𝗲𝗱 𝗰𝗮𝗿𝗲 and why are we not there yet?
ABOUT DAVID EBY, KC
David Eby, K.C.David Eby is the MLA for Vancouver-Point Grey, first elected in 2013.
Before he was elected, David was the Executive Director of the BC Civil Liberties Association, an adjunct professor of law at the University of British Columbia, president of the HIV/AIDS Legal Network, and served on the Vancouver Foundation's Health and Social Development Committee.
An award-winning human rights lawyer, he has been repeatedly recognized in local media as one of British Columbia's most effective advocates and has appeared at all levels of court in BC.
His years of legal advocacy at Pivot Legal Society to protect the human rights and dignity of homeless and under-housed residents of Vancouver's Downtown Eastside were recognized in 2011 by the UN Association in Canada and the B.C. Human Rights Coalition with their annual award.
28:36 Mapping synergy betwen frontline healthcare providers and public health in Canada
31:03 At the intersection of climate change and public health planning
35:09 What does Dr. Tam have to say to the next generation of leaders on the front line and potentially leaders in public
health?
--------
🎙️ ABOUT DR.THERESA TAM
Dr. Theresa Tam was named Canada's Chief Public Health Officer on June 26, 2017. She is a paediatric infectious disease specialist with expertise in immunization, emergency preparedness and global health security.
Dr. Tam obtained her medical degree from the University of Nottingham in the U.K. She completed her paediatric residency at the University of Alberta and her fellowship in paediatric infectious diseases at the University of British Columbia.
She is a Fellow of the Royal College of Physicians and Surgeons of Canada and has over 55 peer-reviewed journal publications in public health. She is also a graduate of the Canadian Field Epidemiology Program.
Dr. Tam has held several senior leadership positions at the Public Health Agency of Canada, including as the Deputy Chief Public Health Officer and the Assistant Deputy Minister for Infectious Disease Prevention and Control. During her 25 years in public health, she provided technical expertise and leadership on new initiatives to improve communicable disease surveillance, enhance immunization programs, strengthen health emergency management and laboratory biosafety and biosecurity. She has played a leadership role in Canada's response to public health emergencies including severe acute respiratory syndrome (SARS), pandemic influenza H1N1 and Ebola.
Dr. Tam has served as an international expert on a number of World Health Organization committees and has participated in multiple international missions related to SARS, pandemic influenza and polio eradication.
As an infectious disease specialist, Dr.Zain Chagla has given media interviews on the COVID-19 pandemic and published several op-eds on testing, disease elimination, and public health interventions. He has contributed to local, provincial, and federal policy planning, and to several clinical trials on COVID-19 therapies. He has published works on COVID-19 research, epidemiology, testing, and infection control. He is involved with a prospective cohort study looking at respiratory physiology and radiologic features of patients post covid with persistent symptoms over time, including those with long covid and those who were critically ill.
Dr.Cheung is the co-lead of CANCOV (Canadian COVID-19 Prospective Cohort Study) as well as RECLAIM (REcovering from COVID‑19 Lingering symptoms Adaptive Integrative Medicine) trial, a Canada-wide, open-label, pragmatic, adaptive randomized clinical trial platform to assess the effectiveness of various interventions in patients with lingering symptoms of COVID‑19.
Dr.Zain Chagla, MD MSc MD, FRCPC is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla is also a teacher at McMaster University where he won a clinician teaching award in internal medicine and a young investigator grant for his work in supporting undergraduate medical education at the University of Namibia.
Dr. Chagla also has a Master of Science in infectious diseases and a diploma in tropical medicine and hygiene from the London School of Hygiene & Tropical Medicine.
As an infectious disease specialist, Dr.Zain Chagla has given media interviews on the COVID-19 pandemic and published several op-eds on testing, disease elimination, and public health interventions. He has contributed to local, provincial, and federal policy planning, and to several clinical trials on COVID-19 therapies. He has published works on COVID-19 research, epidemiology, testing, and infection control. He is involved with a prospective cohort study looking at respiratory physiology and radiologic features of patients post covid with persistent symptoms over time, including those with long covid and those who were critically ill.
Dr.Cheung is the co-lead of CANCOV (Canadian COVID-19 Prospective Cohort Study) as well as RECLAIM (REcovering from COVID‑19 Lingering symptoms Adaptive Integrative Medicine) trial, a Canada-wide, open-label, pragmatic, adaptive randomized clinical trial platform to assess the effectiveness of various interventions in patients with lingering symptoms of COVID‑19.
Dr.Zain Chagla, MD MSc MD, FRCPC is an associate professor at McMaster University, co-medical director of infection control at St. Joseph’s Healthcare Hamilton and a consultant in infection control at Woodstock General Hospital. Dr. Chagla is also a teacher at McMaster University where he won a clinician teaching award in internal medicine and a young investigator grant for his work in supporting undergraduate medical education at the University of Namibia.
Dr. Chagla also has a Master of Science in infectious diseases and a diploma in tropical medicine and hygiene from the London School of Hygiene & Tropical Medicine.
As an infectious disease specialist, Dr.Zain Chagla has given media interviews on the COVID-19 pandemic and published several op-eds on testing, disease elimination, and public health interventions. He has contributed to local, provincial, and federal policy planning, and to several clinical trials on COVID-19 therapies. He has published works on COVID-19 research, epidemiology, testing, and infection control. He is involved with a prospective cohort study looking at respiratory physiology and radiologic features of patients post covid with persistent symptoms over time, including those with long covid and those who were critically ill.
